Publisher · 6 documents · 61 figures
NHSA (National Healthcare Security Administration)
61 verified figures from 6 publications by NHSA, a government body. Every figure links to the document and sentence it came from.
Documents used
Every publication we have taken a number from, with the date we read it and the link status at that time.
| Document | Type | Published | Retrieved | Link | Data points |
|---|---|---|---|---|---|
| 国家医保局 人力资源社会保障部印发2024年版国家医保药品目录 Licence: See source | Press release | 28 Nov 2024 | 17 Sep 2026 | Reachable | 12 |
| 国新办举行国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况 Licence: See source | Press release | — | 17 Sep 2026 | Reachable | 4 |
| 我国上半年创新药对外授权交易额超千亿美元 Licence: See source | Press release | — | 17 Sep 2026 | Reachable | 11 |
| 从“0”到“1”创新能力增强 我国新药研发热度持续攀升 Licence: See source | Press release | — | 17 Sep 2026 | Reachable | 12 |
| 国家医保局 人力资源社会保障部印发2025年版国家基本医疗保险、生育保险和工伤保险药品目录和商业健康保险创新药品目录 Licence: See source | Press release | — | 17 Sep 2026 | Reachable | 6 |
| 创新高！去年我国批准创新药76个 对外授权破千亿美元 Licence: See source | Press release | — | 17 Sep 2026 | Reachable | 16 |
Measures from this publisher
Every measure taken from NHSA, with its latest value and trend. Each value opens its record.
Market size and output 13
Show 7 more measures
- Imported innovative chemical drug approvals 9
- Innovative biological product approvals 23
- Innovative biological product approvals (half year) 17
- Innovative drug approvals (year to date) 14
- Innovative traditional medicine approvals 6
- Innovative traditional medicine approvals (half year) 1
- Radiopharmaceutical market size 26 billion CNY
Prices and costs 2
Adoption and share 6
Growth and change 3
Other measures 32
Show 26 more measures
- Approved innovative drugs with new targets or mechanisms 11
- Approved innovative drugs with new targets or mechanisms (half year) 11
- Beneficiaries of negotiated reimbursement drugs 830 million person-visits
- Bioequivalence trials 2,218
- Category 1 innovative drugs added to national health insurance catalog 50
- Centralized procurement drugs added to national reimbursement drug list 2
- Class 1 innovative drug clinical trials 2,171
- Cumulative drugs added via negotiation in reimbursement drug list 530
- Cumulative drugs removed from reimbursement drug list 438
- Cumulative newly added drugs in reimbursement drug list 835
- Drugs in commercial health insurance innovative drug catalog (annual) 19
- Drugs removed from national reimbursement drug list 29
- Drugs removed from national reimbursement drug list (year to date) 43
- Innovative drug out-licensing deal count (half year) 81
- Innovative drug out-licensing deal value (half year) 110 billion USD
- International multi-center clinical trials 410
- Negotiated or bid drugs added to national reimbursement drug list 89
- New drug clinical trial initiation time reduction 4 months
- New drugs approved for marketing after clinical trials (China registration category) 248
- Newly added drugs in national reimbursement drug list 91
- Newly added drugs in national reimbursement drug list (annual) 114
- Reimbursement drug list total drugs 3,159
- Reimbursement drug list total drugs (annual) 3,253
- Reimbursement drug list traditional patent medicines 1,394
- Reimbursement drug list traditional patent medicines (annual) 1,396
- Top 50 global pharmaceutical companies count 6
56 measures. Each name opens the full series; each value opens the record with its source evidence.
Cite this page
Data on this page is published under CC BY 4.0. Credit National Healthcare Security Administration as the original publisher; each record page carries its own citation.
National Healthcare Security Administration. Retrieved from StatOrigin: https://statorigin.org/sources/national-healthcare-security-administration
Related
Industries using this source
Last verified 27 September 2026. Link status is rechecked weekly.